Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy
MC Cox-Froncillo, M Cantonetti, M Masi… - Cancer genetics and …, 1995 - Elsevier
Cytogenetic analysis is considered pivotal for assessing the remission rate in CML patients
on IFN therapy. On the basis of general agreement, at least 25 metaphases should be …
on IFN therapy. On the basis of general agreement, at least 25 metaphases should be …
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy
M Cox Froncillo, M Cantonetti, M Masi… - CANCER GENETICS …, 1995 - art.torvergata.it
Cytogenetic analysis is considered pivotal for assessing the remission rate in CML patients
on IFN therapy. On the basis of general agreement, at least 25 metaphases should be …
on IFN therapy. On the basis of general agreement, at least 25 metaphases should be …
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-alpha (IFN-alpha) therapy
MC Cox-Froncillo, M Cantonetti… - Cancer genetics …, 1995 - pubmed.ncbi.nlm.nih.gov
Cytogenetic analysis is considered pivotal for assessing the remission rate in CML patients
on IFN therapy. On the basis of general agreement, at least 25 metaphases should be …
on IFN therapy. On the basis of general agreement, at least 25 metaphases should be …
[引用][C] Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy
MC COX-FRONCILLO, M CANTONETTI… - Cancer genetics …, 1995 - pascal-francis.inist.fr
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid
leukemia (CML) patients on interferon-α (IFN-α) therapy CNRS Inist Pascal-Francis CNRS …
leukemia (CML) patients on interferon-α (IFN-α) therapy CNRS Inist Pascal-Francis CNRS …
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-alpha (IFN-alpha) therapy.
MC Cox-Froncillo, M Cantonetti, M Masi… - Cancer Genetics and …, 1995 - europepmc.org
Cytogenetic analysis is considered pivotal for assessing the remission rate in CML patients
on IFN therapy. On the basis of general agreement, at least 25 metaphases should be …
on IFN therapy. On the basis of general agreement, at least 25 metaphases should be …
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy
MC Cox-Froncillo, M Cantonetti… - Cancer Genetics …, 1995 - cancergeneticsjournal.org
Cytogenetic analysis is considered pivotal for assessing the remission rate in CML patients
on IFN therapy. On the basis of general agreement, at least 25 metaphases should be …
on IFN therapy. On the basis of general agreement, at least 25 metaphases should be …